

19 October 2026

Board Renewal

PHOENIX USA, 19 October 2026: Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), advises that Australian resident Non-Executive Directors Dr Stewart Washer and Mr Danny Sharp resigned from the Board, effective immediately, on Saturday 17 October 2026.

Company Secretary Mr Andrew Bickley and Chief Financial Officer (Australia) Mr Graeme Morissey, both ordinarily resident in Australia, have been appointed as interim Non-Executive and Executive Director respectively, to fill the casual vacancies. The appointments are in accordance with the Botanix Constitution and became effective on 18 October 2026. Given their existing officer roles, Messrs Bickley and Morissey will not be classified as independent Directors.

Executive Chairman Vince Ippolito said: ‘We welcome Mr Bickley and Mr Morissey to the Board. Their governance and financial backgrounds respectively will be of real assistance to the Board at this important time. Their appointment as interim Directors will allow us the time to conduct a careful search for replacement Australian resident independent Non-Executive Directors to join the Board for the longer term, having regard to the best skill and experience mix to drive growth for the Company.’

Mr Bickley joined Botanix in October 2025. He has more than 15 years’ experience in corporate governance, legal and advisory roles across Australian and international organisations, including listed companies, professional services firms and statutory agencies. Mr Bickley has extensive experience advising boards and senior executives on corporate governance and listed company matters. Mr Bickley holds a Bachelor of Laws from the University of Essex and is a Fellow of both the Governance Institute of Australia and the Chartered Governance Institute.

Mr Morissey joined Botanix in March 2024. Mr Morissey is a Chartered Accountant with extensive experience across the resources sector, including serving as Chief Financial Officer of a number of ASX-listed mining and mineral exploration companies. His experience spans equity and debt capital markets, mergers and acquisitions, corporate governance and the financial management of mining and exploration activities across multiple jurisdictions. Mr Morissey began his career in public practice and spent 15 years with EY, KPMG and Grant Thornton, including as a Director. He is currently a director of Heavy Rare Earths Limited (ASX: HRE) and Jacaranda Resources Limited, which is undertaking an initial public offering ahead of a proposed ASX listing.

In addition to their current officer arrangements, Messrs Bickley and Morissey will be paid a further A\$40,000 per annum respectively, monthly in arrears, for taking on the Director roles.

Appointed as casual vacancies, Messrs Bickley and Morissey will hold office until the 2026 Annual General Meeting scheduled for 30 November 2026, where they will stand for election in accordance with the Constitution and the Listing Rules. More details will be provided in the Notice of Meeting.

This ASX release was authorised by the Botanix Pharmaceuticals Ltd Board of Directors.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: www.botanixpharma.com

For more information, please contact:

General enquiries
Botanix Pharmaceuticals
Corporate Communications
P: [+61 8 6285 0083](tel:+61862850083)
info@botanixpharma.com

Investor and Media Relations
Jane Morgan Management
Wilamina Russo
P: [+61 450 646 609](tel:+61450646609)
wr@janemorganmanagement.com.au

Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra* and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.